dm+d

Unassigned

New Medicines

Pulmonary non-tubercular mycobacterial disease, also known as Mycobacterium avium complex (MAC)

Information

New formulation
RedHill Biopharma
RedHill Biopharma

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Broad spectrum antimycobacterial agents
Non-Tuberculous Mycobacteria (NTM) is a debilitating disease that can cause scarring, fibrosis and the formation of cavities or pits in the lungs, which can lead to potentially fatal respiratory failure. People with existing lung conditions, such as bronchiectasis and those with COPD, are particularly susceptible [1].
Pulmonary non-tubercular mycobacterial disease, also known as Mycobacterium avium complex (MAC)
Oral

Crohn's disease secondary to Mycobacterium avium ssp. paratuberculosis (MAP)

Information

New formulation
RedHill Biopharma
RedHill Biopharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Combination with intracellular, antimycobacterial and anti-inflammatory properties
Mycobacterium avium subspecies paratuberculosis is often abbreviated M. paratuberculosis. It is estimated that more than 115,000 people have Crohns disease in the UK.
Crohn's disease secondary to Mycobacterium avium ssp. paratuberculosis (MAP)
Oral